Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methotrexate + mitomycin C + mitoxantrone + tamoxifen
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination involves four drugs: methotrexate, an antifolate used in chemotherapy; mitomycin C, an alkylating agent; mitoxantrone, an anthracenedione antineoplastic; and tamoxifen, a selective estrogen receptor modulator. The combination is not commonly used under a specific brand name but represents a mix of antineoplastic and hormonal therapies.
- Other names
- MMM + Tamoxifen3M + Tamoxifen
02
Targets
DNADHFR (Dihydrofolate reductase)ER (Estrogen receptor)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on methotrexate + mitomycin C + mitoxantrone + tamoxifen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methotrexate + mitomycin C + mitoxantrone + tamoxifen.